Fulcrum Therapeutics Ownership | Who Owns Fulcrum Therapeutics?

Overview ForecastFinancials Chart Transcripts

Fulcrum Therapeutics Ownership Summary

Fulcrum Therapeutics is owned by 9.18% institutional investors, 1.19% insiders, and 89.64% retail investors. Ra capital management is the largest institutional shareholder, holding 16.36% of FULC shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.43% of its assets in Fulcrum Therapeutics shares.

FULC Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Fulcrum Therapeutics	9.18%	1.19%	89.64%
Sector	Healthcare Stocks	232.01%	10.74%	-142.75%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ra capital management	10.23M	16.36%	$94.11M
Suvretta capital management	5.38M	8.60%	$49.51M
Tcg crossover management	5.25M	8.39%	$48.30M
Blackrock	4.80M	7.74%	$29.75M
Nantahala capital management	4.29M	6.86%	$48.56M
Blackrock funding, inc. /de	4.26M	6.81%	$48.22M
Vanguard group	3.56M	5.69%	$40.26M
Adage capital partners gp	2.43M	3.89%	$22.37M
Gsk	1.79M	2.85%	$20.20M
Logos global management lp	1.50M	2.42%	$9.30M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mass general brigham	205.36K	6.20%	$1.27M
Allostery investments lp	40.35K	3.54%	$277.63K
Gsk	1.79M	2.53%	$20.20M
Tcg crossover management	5.25M	2.38%	$48.30M
Nantahala capital management	4.29M	1.61%	$48.56M
Suvretta capital management	5.38M	1.27%	$49.51M
Ikarian capital	1.29M	1.20%	$11.86M
Ra capital management	10.23M	1.16%	$94.11M
Logos global management lp	1.50M	0.75%	$9.30M
Silverarc capital management	394.65K	0.62%	$4.46M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	4.80M	0.00%	3.26M
Gsk	1.79M	2.53%	1.79M
Balyasny asset management	1.34M	0.01%	1.34M
Abrdn	1.25M	0.02%	1.12M
Royal bank of canada	1.00M	0.00%	996.63K

Top Sellers

Holder	Shares	% Assets	Change
Rtw investments, lp	-	-	-5.85M
Cowen and company	-	-	-2.96M
Trv gp iv	-	-	-2.34M
Adage capital partners gp	2.43M	0.04%	-2.16M
Bioimpact capital	-	-	-1.44M

New Positions

Holder	Shares	% Assets	Change	Value
Gsk	1.79M	2.53%	1.79M	$20.20M
Balyasny asset management	1.34M	0.01%	1.34M	$9.21M
Silverarc capital management	394.65K	0.62%	394.65K	$4.46M
Braidwell lp	219.49K	0.06%	219.49K	$2.02M
Ameriprise financial	124.67K	0.00%	124.67K	$1.15B

Sold Out

Holder	Change
Zurcher kantonalbank (zurich cantonalbank)	-3.00
Newedge advisors	-3.00
Clearstead advisors	-4.00
Larson financial group	-15.00
Lindbrook capital	-74.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	31	-76.69%	5,744,707	-89.33%	9	0.12%	15	-77.61%	9	-78.57%
Sep 30, 2025	41	-68.22%	4,755,539	-91.26%	7	0.10%	18	-68.97%	11	-76.60%
Jun 30, 2025	128	7.56%	54,400,559	5.91%	86	1.29%	58	23.40%	46	4.55%
Mar 31, 2025	118	-7.81%	51,275,989	-0.70%	82	1.20%	47	-14.55%	44	-2.22%
Dec 31, 2024	128	-15.23%	51,635,187	-5.98%	82	1.07%	55	-29.49%	45	25.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	1.85M	3.43%	-
Vanguard Total Stock Mkt Idx Inv	2.07M	3.11%	-
Fidelity Growth Compy Commingled Pl O	1.35M	2.16%	-464.60K
abrdn Life Sciences Investors	1.37M	2.05%	113.59K
Fidelity Select Biotechnology	1.14M	1.83%	-111.80K
iShares Russell 2000 ETF	1.05M	1.57%	301.67K
Fidelity Select Pharmaceuticals Port	683.60K	1.10%	-
Fidelity Growth Compy Commingled Pl S	494.64K	0.92%	-295.57K
SPDR® S&P Pharmaceuticals ETF	436.70K	0.81%	-
Vanguard Institutional Extnd Mkt Idx Tr	522.32K	0.78%	2.35K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 02, 2026	Gould Robert J	-	Sell	$163.09K
Feb 02, 2026	Gould Robert J	-	Sell	$160.86K
Jan 02, 2026	Gould Robert J	-	Sell	$178.09K
Dec 15, 2025	Oltmans Curtis Gale	Chief Legal Officer	Sell	$44.60K
Dec 08, 2025	RA CAPITAL MANAGEMENT, L.P.	-	Sell	$38.65M

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	3
2025 Q4	-	5
2025 Q2	-	1
2025 Q1	-	-
2024 Q4	-	-

FULC Ownership FAQ

Who Owns Fulcrum Therapeutics?

Fulcrum Therapeutics shareholders are primarily institutional investors at 9.18%, followed by 1.19% insiders and 89.63% retail investors. The average institutional ownership in Fulcrum Therapeutics's industry, Biotech Stocks , is 381.47%, which Fulcrum Therapeutics falls below.

Who owns the most shares of Fulcrum Therapeutics?

Fulcrum Therapeutics’s largest shareholders are Ra capital management (10.23M shares, 16.36%), Suvretta capital management (5.38M shares, 8.60%), and Tcg crossover management (5.25M shares, 8.39%). Together, they hold 33.35% of Fulcrum Therapeutics’s total shares outstanding.

Does Blackrock own Fulcrum Therapeutics?

Yes, BlackRock owns 7.74% of Fulcrum Therapeutics, totaling 4.8M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 29.75M$. In the last quarter, BlackRock increased its holdings by 3.26M shares, a 211.35% change.

Who is Fulcrum Therapeutics’s biggest shareholder by percentage of total assets invested?

Mass general brigham is Fulcrum Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.20% of its assets in 205.36K Fulcrum Therapeutics shares, valued at 1.27M$.

Who is the top mutual fund holder of Fulcrum Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Fulcrum Therapeutics shares, with 3.43% of its total shares outstanding invested in 1.85M Fulcrum Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools